Research programme: chemoprotection - Sound Pharmaceuticals

Drug Profile

Research programme: chemoprotection - Sound Pharmaceuticals

Alternative Names: Allopurinol/ebselen; Chemoprevention research programme - Sound Pharmaceuticals; Chemoprotection research programme - Sound Pharmaceuticals; Ebselen/allopurinol; Research programme: chemoprevention - Sound Pharmaceuticals; SPI-3005/6

Latest Information Update: 30 Nov 2010

Price : $50

At a glance

  • Originator Sound Pharmaceuticals
  • Class Chemopreventatives; Chemoprotectants; Purines; Small molecules
  • Mechanism of Action Glutathione peroxidase stimulants; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Sensorineural hearing loss

Most Recent Events

  • 30 Nov 2010 Discontinued - Preclinical for Sensorineural hearing loss(chemotherapy-induced, prevention) in USA (PO)
  • 24 Feb 2004 Preclinical trials in Sensorineural hearing loss(chemotherapy-induced, prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top